Literature DB >> 10545730

Subacute liver failure induced by phenprocoumon treatment.

H Mix1, S Wagner, K Böker, S Gloger, K J Oldhafer, M Behrend, P Flemming, M P Manns.   

Abstract

We report on a 39-year-old woman suffering from deep venous thrombosis due to a heterozygous factor-V-Leiden mutation with resistance to activated protein C. Four months after beginning oral anticoagulation, generalized jaundice appeared. Subsequently, subacute liver failure developed necessitating an orthotopic liver transplantation. Histopathology showed features of extensive liver cell necrosis without evidence of a substantial inflammatory infiltrate. Based on histopathology and exclusion of other liver diseases, phenprocoumon-induced liver failure was diagnosed. Five months after transplantation the patient is well with normal liver function tests. Because of the widespread use of oral anticoagulants, not only bleeding complications but also hepatotoxicity should be considered in therapy supervision.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 10545730     DOI: 10.1159/000007710

Source DB:  PubMed          Journal:  Digestion        ISSN: 0012-2823            Impact factor:   3.216


  4 in total

1.  [Unclear hepatopathy in a patient with atrial fibrillation].

Authors:  C Pennartz; H Schrader; P R Ritter; A Tannapfel; W E Schmidt; J J Meier
Journal:  Internist (Berl)       Date:  2012-01       Impact factor: 0.743

2.  [Role of vitamin K antagonists from a hepatologist's point of view].

Authors:  G Kneiseler; A Canbay; G Gerken
Journal:  Herz       Date:  2012-06       Impact factor: 1.443

3.  Coumarin embryopathy in an extremely low birth weight infant associated with neonatal hepatitis and ocular malformations.

Authors:  Patrick G Hetzel; René Glanzmann; Pascal W Hasler; Ariane Ladewick; Christoph Bührer
Journal:  Eur J Pediatr       Date:  2006-01-13       Impact factor: 3.183

4.  Evidence for immunological (allergic) mechanisms in a subgroup of patients with phenprocoumon-induced liver disease.

Authors:  Reinhild Klein
Journal:  Eur J Clin Pharmacol       Date:  2009-12       Impact factor: 2.953

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.